Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today announced its intention to pursue an initial …